| Filed On | Filing |
|---|---|
| 13 Nov 2026 | 10-Q |
| 13 Nov 2026 |
8-K: Results of Operations and Financial Condition
JADE101 Phase 3 registrational trial in IgA nephropathy (EVERGREEN) expected to initiate in the fourth quarter of 2026 |
| 28 Oct 2026 | SCHEDULE 13G |
| 27 Oct 2026 | SCHEDULE 13G |
| 30 Sep 2026 |
8-K: Other Events
On September 30, 2026, Jade Biosciences, Inc. (“Jade”) announced preclinical data characterizing JADE301, its anti-interferon beta (“IFN-ß”) monoclonal antibody in development for dermatomyositis (“DM”), a rare, chronic and debilitating ... |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 10 Aug 2026 | 10-Q |
| 10 Aug 2026 |
8-K: Results of Operations and Financial Condition
Announced positive interim Phase 1 results for JADE101 demonstrating potential for every 12-week subcutaneous dosing and best-in-class clinical activity in IgA nephropathy |
| 17 Jul 2026 | SCHEDULE 13G |
| 08 Jul 2026 | SCHEDULE 13G/A |
| 01 Jul 2026 |
8-K: Entry into a Material Definitive Agreement
On June 29, 2026, Jade Biosciences, Inc. (the “Company”) entered into a License Agreement (the “JADE301 License Agreement”) with Paragon Therapeutics, Inc. (“Paragon”), pursuant to which Paragon granted the Company a royalty-bearing, wor... |
| 26 Jun 2026 |
Form 4: Eisner Mark, Director
Granted 47,675 Stock Option (Right to Buy) |
| 26 Jun 2026 |
Form 3: Eisner Mark, Director
No securities owned |
| 26 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
San Francisco and Vancouver, British Columbia, June 26, 2026 — Jade Biosciences, Inc. (the “Company” or “Jade”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases,... |
| 11 Jun 2026 |
Form 4: Cain Christopher W., Director
Granted 34,843 Stock Option (Right to Buy) |
| 11 Jun 2026 |
Form 4: Dobmeier Eric, Director
Granted 34,843 Stock Option (Right to Buy) |
| 11 Jun 2026 |
Form 4: Klein Lawrence Otto, Director
Granted 34,843 Stock Option (Right to Buy) |
| 11 Jun 2026 |
Form 4: Lavelle Erin, Director
Granted 34,843 Stock Option (Right to Buy) |
| 11 Jun 2026 |
Form 4: Fairmount Funds Management Llc, Director and 4 others
Granted 34,843 Stock Option (Right to Buy) |
Loading...